Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Humanwell Healthcare (Group) Co's Other Operating Expense for the
three
months ended in Mar. 2026 was ¥2 Mil.
Its Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was ¥2,483 Mil.
Humanwell Healthcare (Group) Co's quarterly Other Operating Expense
increased
from Sep. 2025 (¥-1,279 Mil) to Dec. 2025 (¥2,421 Mil) but then
declined
from Dec. 2025 (¥2,421 Mil) to Mar. 2026 (¥2 Mil).
Humanwell Healthcare (Group) Co's annual Other Operating Expense
increased
from Dec. 2023 (¥2,222 Mil) to Dec. 2024 (¥2,719 Mil) but then
declined
from Dec. 2024 (¥2,719 Mil) to Dec. 2025 (¥2,491 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanwell Healthcare (Group) Co Other Operating Expense Chart
Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)
Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.
Other Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥2,483 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Other Operating Expense of ¥2,483 Mil mean?
Humanwell Healthcare (Group) Co (SHSE:600079) has a Other Operating Expense of ¥2,483 Mil as of Mar. 2026. Other operating expenses that a company records on its income statement. View historical data on Humanwell Healthcare (Group) Co and its competitors.
Is Humanwell Healthcare (Group) Co's Other Operating Expense too high?
Humanwell Healthcare (Group) Co's current Other Operating Expense is ¥2,483 Mil. Overall, Humanwell Healthcare (Group) Co has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Humanwell Healthcare (Group) Co's Other Operating Expense compare to ZTS?
Humanwell Healthcare (Group) Co's Other Operating Expense of ¥2,483 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Operating Expense for a Drug Manufacturers company?
A good Other Operating Expense depends on the Drug Manufacturers industry context. However, Other Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Operating Expense mean?
A high Other Operating Expense can signal that a stock is expensive relative to its fundamentals. Other operating expenses that a company records on its income statement. View historical data on Humanwell Healthcare (Group) Co and its competitors. Humanwell Healthcare (Group) Co's current Other Operating Expense is ¥2,483 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Humanwell Healthcare (Group) Co stock overvalued right now?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co (SHSE:600079) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥21.88, compared to a current price of ¥17.67 — trading 19.2% below its estimated fair value. The current Other Operating Expense is ¥2,483 Mil. Humanwell Healthcare (Group) Co's overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Operating Expense calculated?
Other Operating Expense is calculated from a company's financial statements. For Humanwell Healthcare (Group) Co (SHSE:600079), the current Other Operating Expense is ¥2,483 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Humanwell Healthcare (Group) Co (SHSE:600079) Overvalued in 2026?
Based on GuruFocus' analysis, Humanwell Healthcare (Group) Co stock appears to be undervalued.
The current stock price of ¥17.67 is trading 19.2% below its estimated GF Value™ of ¥21.88.
GuruFocus considers Humanwell Healthcare (Group) Co to be Modestly Undervalued.
Key valuation signals for SHSE:600079:
Other Operating Expense: ¥2,483 Mil
GF Value™: ¥21.88 vs. price of ¥17.67 (19.2% below fair value)
No single metric tells the full story. See the SHSE:600079 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Humanwell Healthcare (Group) Co Ltd is a China-based integrated healthcare solution provider. It provides medicinal products including fertility-regulating drugs, Uyghur medicine, traditional Chinese medicine, medical devices, over-the-counter medicines, anti-infection drugs, herbal medicines, and biological products. The organization has a business presence in China and other international countries.
60GF Score
Get the complete analysis for SHSE:600079
Other Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600079 has been successfully added to your 
